Get the Stockscreener App
1.74
0.58%
0.01
After Hours:
1.74
Immutep Limited Adr stock is traded at $1.74, with a volume of 46,848.
It is up +0.58% in the last 24 hours and down -7.94% over the past month.
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
See More
Previous Close:
$1.73
Open:
$1.74
24h Volume:
46,848
Relative Volume:
0.17
Market Cap:
$270.74M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-7.7437
EPS:
-0.2247
Net Cash Flow:
-
1W Performance:
-6.45%
1M Performance:
-7.94%
6M Performance:
-20.18%
1Y Performance:
-36.26%
1-Day Range:
$1.71
$1.80
1-Week Range:
$1.71
$1.92
52-Week Range:
$1.32
$2.80
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.74 | 270.74M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-17-24 | Initiated | CapitalOne | Overweight |
| Aug-03-23 | Initiated | Robert W. Baird | Outperform |
| Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
| Jul-16-21 | Resumed | Maxim Group | Buy |
| Sep-28-18 | Initiated | B. Riley FBR | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
View All
Immutep Limited Adr Stock (IMMP) Latest News
Jane Street Group LLC Has $98,000 Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks
Market Highlights: Immutep Limited ADR (IMMP) Ends on a Low Note at 1.93 - DWinneX
Immutep stock soars on promising trial results - Investing.com Australia
Immutep stock soars on promising trial results By Investing.com - Investing.com Nigeria
Immutep Quarterly Activities Report Q3 FY25 - The Manila Times
Immutep to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Immutep Limited (ASX:IMM) Initiates Phase III Trial for Non-Small Cell Lung Cancer - thecapitalclub.com.au
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - Yahoo Finance
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - Yahoo Finance
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 - GlobeNewswire
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep LimitedADR (IMMP) Price Target Increased by 5.10% to 2.59 - Nasdaq
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - Targeted Oncology
Best Penny Stocks To Buy For 2021? 5 Biotech Stocks To Watch - Penny Stocks
IMMPImmutep Latest Stock News & Market Updates - Stock Titan
Immutep Ltd (IMMP) Stock Price, Trades & News - GuruFocus
A Full List of Australia ADRs - Investing.com Australia
Immutep (IMMP) Stock Price, News & Analysis - MarketBeat
Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia
Prima BioMed Stock Price Today | NASDAQ: IMMP Live - Investing.com
Prima BioMed Stock Price Today | NASDAQ IMMP - Investing.com Canada
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - advfn.com
Immutep Limited Adr Stock (IMMP) Financials Data
There is no financial data for Immutep Limited Adr (IMMP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):